In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Iain Dukes Biography and Net Worth

Director of Iovance Biotherapeutics

Dr. Dukes joined the Iovance Board of Directors and was appointed Chairman of the Board in August 2016. Dr. Dukes is a Venture Partner at OrbiMed Advisors. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research and Development at Amgen. He has also served as President and Chief Executive Officer, as well as a member of the Board of Directors of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Previously, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes serves on the Board of Directors of Themis Biosciences, Ikena Oncology, KaNDy Therapeutics (previously as Chairman), NeRRe Therapeutics, ReViral Limited and ENYO Therapeutics. Dr. Dukes co-founded and is the former Chief Executive Officer of Theseus Pharmaceuticals. He also co-founded and serves on the Board of Directors of Kartos Therapeutics, and co-founded Telios Pharma, where he serves as President. He holds an M.J. and D.Phil. from the University of Oxford, an M.S. in Cardiovascular Studies from the University of Leeds, and a B.S. in Pharmacology from the University of Bath.

What is Iain D. Dukes' net worth?: The estimated net worth of Iain D. Dukes is at least $183,260.00 as of November 23rd, 2022. Dr. Dukes owns 22,000 shares of Iovance Biotherapeutics stock worth more than $183,260 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Dukes may own. Learn More about Iain D. Dukes' net worth.
How do I contact Iain D. Dukes?: The corporate mailing address for Dr. Dukes and other Iovance Biotherapeutics executives is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. Iovance Biotherapeutics can also be reached via phone at (650) 260-7120 and via email at [email protected]. Learn More on Iain D. Dukes' contact information.
Has Iain D. Dukes been buying or selling shares of Iovance Biotherapeutics?: Iain D. Dukes has not been actively trading shares of Iovance Biotherapeutics in the last ninety days. Most recently, on Wednesday, November 23rd, Iain D. Dukes bought 10,000 shares of Iovance Biotherapeutics stock. The stock was acquired at an average cost of $6.10 per share, with a total value of $61,000.00. Following the completion of the transaction, the director now directly owns 22,000 shares of the company's stock, valued at $134,200. Learn More on Iain D. Dukes' trading history.
Who are Iovance Biotherapeutics' active insiders?: Iovance Biotherapeutics' insider roster includes Iain Dukes (Director), Wayne Rothbaum (Director), and Frederick Vogt (CEO). Learn More on Iovance Biotherapeutics' active insiders.
Are insiders buying or selling shares of Iovance Biotherapeutics?: In the last twelve months, Iovance Biotherapeutics insiders bought shares 1 times. They purchased a total of 250,000 shares worth more than $2,287,500.00. In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 50,000 shares worth more than $503,000.00. The most recent insider tranaction occured on November, 12th when Director Ryan D Maynard sold 50,000 shares worth more than $503,000.00. Insiders at Iovance Biotherapeutics own 12.1% of the company. Learn More about insider trades at Iovance Biotherapeutics.
Information on this page was last updated on 11/12/2024.

Iain D. Dukes Insider Trading History at Iovance Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/23/2022	Buy	10,000	$6.10	$61,000.00	22,000
12/18/2018	Buy	12,000	$8.65	$103,800.00	12,000

Iain D. Dukes Buying and Selling Activity at Iovance Biotherapeutics

Iovance Biotherapeutics Company Overview

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Today's Range

Now: $8.33

$7.98

$8.38

50 Day Range

MA: $9.97

$8.14

$12.28

2 Week Range

Now: $8.33

$5.24

$18.33

Volume

2,170,833 shs

Average Volume

7,307,576 shs

Market Capitalization

$2.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad